About Carmot
Carmot is a Healthcare company based in Berkeley (United States) founded in 2008, and was acquired by Roche in December 2023. Disease-modifying therapies for metabolic diseases are developed. Carmot has raised $385.52 million across 17 funding rounds from investors including Amgen, Roche and HHS. Its chief executive, as recorded, is Heather Turner. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Obesity. Its legal entity is Carmot Therapeutics Inc. Its competitors include Altimmune, BioAge Labs and Fractyl; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2008 in Berkeley, United States, and focuses on biotechnology for metabolic disorders. A drug discovery platform is utilized to identify incretin receptor signaling targets, supporting a pipeline of therapeutics aimed at obesity and diabetes. Three clinical candidatesCT-388, CT-868, and CT-996are advanced through development stages. Operations center on innovative treatments without emphasis on broader services.
Funding Insights of Carmot
Carmot has successfully raised a total of $385.52M across 17 strategic funding rounds. The most recent funding activity was a Series E round of $150 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $385.52M
- Total Rounds 17
- Last Round Series E — $150M
- First Round $199,998
(Oct 2009)
- Investors Count 19
Latest 10 of 17 funding rounds of Carmot with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $150M | Series E | – | Deep Track Capital | |
| Jul 2022 | $160.67M | Series D | – | TCG | |
| Sep 2020 | $47M | Series C | – | Amgen | |
| Jan 2018 | $15M | Series B | – | Horizons Ventures, TCG | |
| Aug 2017 | $10.8M | Series A | – | – | – |
| Sep 2012 | $541,527 | Grant | – | – | |
| Jul 2012 | $500,159 | Seed | – | – | – |
| Sep 2011 | $1.12M | Grant | – | – | |
| Aug 2011 | $1.12M | Grant | – | – | |
| Jul 2011 | $299,807 | Grant | – | – |
19 investors in total: 18 institutional and 1 angel.
Investors in Carmot
Carmot has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amgen, Roche and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
| tcgcrossover.com | ||||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Philanthropic assets are managed by Willett Advisors LLC. | willettadvisors.com | New York, United States | ||
Horizons Ventures is focused on investing in deep science and technology. | horizonsventures.com | Hong Kong, China | ||
Venture debt and equity financing is offered to US startups. | leaderventures.com | Palo Alto, United States |
Investor details for Carmot
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Carmot
1 people are tracked at Carmot (1 in leadership).
| Name | Role | Group |
|---|---|---|
Heather Turner | CEO | Leadership |
Complete people profiles for Carmot
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Carmot
4 dated milestones of Carmot across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Carmot is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Series E, of $150.0M.
- Exit Acquired by Roche.
Competitors of Carmot
Carmot has 3 listed competitors in our database, 3 of them funded. They include Altimmune, BioAge Labs and Fractyl.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| fractyl.com | 2010 | Lexington, United States | $345.27M | 79 | Endoscopic procedures for type-2 diabetes treatment are developed. |
Detailed competitors of Carmot
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Carmot (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Carmot
Complete news archive for Carmot
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carmot
Carmot was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Carmot is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Heather Turner is the CEO of Carmot, as recorded in our data.
Carmot is a funded company, having raised a total of $385.52M across 17 funding rounds to date. The company's 1st funding round was a Grant of $299.81K, raised on Oct 2009.
The company was founded in 2008 in Berkeley, United States, and focuses on biotechnology for metabolic disorders. A drug discovery platform is utilized to identify incretin receptor signaling targets, supporting a pipeline of therapeutics aimed at obesity and diabetes. Three clinical candidatesCT-388, CT-868, and CT-996are advanced through development stages. Operations center on innovative treatments without emphasis on broader services.
Carmot's top competitors include BioAge Labs, Fractyl and Altimmune.
Carmot has 19 investors. Key investors include Amgen, Roche, HHS, Schroders, and Janus Henderson Investors.
Carmot operates through Carmot Therapeutics Inc.
Yes. Carmot was acquired by Roche in December 2023.